Celator Pharmaceuticals, Inc.

Under Business Highlights, 3rd bullet should read: A Phase 2 study of CPX-351 in adults with untreated high-risk Myelodysplastic Syndrome and AML (excluding Acute Promyelocytic Leukemia) at high ... read more

Celator Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing new and more effective therapies to treat cancer, today reported first quarter 2013 financial results. ... read more

Celator Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing new and more effective therapies to treat cancer, today announced that it has raised ... read more

Celator Pharmaceuticals today announced the appointment of Lisa DeLuca, Ph.D., as vice president, regulatory affairs. Dr. DeLuca will be responsible for ongoing interactions with global regulatory bodies, ... read more

Celator Pharmaceuticals today announced that the first patient has been treated in its Phase 3, multicenter, randomized, open-label clinical trial of CPX-351 ... read more

Celator Pharmaceuticals today announced the appointment of industry veteran Fred M. Powell, CPA, as chief financial officer. Powell will be responsible for the Company's accounting, corporate finance, financial ... read more

Celator Pharmaceuticals today announced new data on previously untreated elderly patients with acute myeloid leukemia (AML) and multiple-risk factors treated with CPX-351 (cytarabine:daunorubicin) Liposome ... read more